Practice areas: Business & Corporate, Mergers & Acquisitions, Closely Held Business; view more
Licensed in California since: 1985
Education: University of California Los Angeles (UCLA) School of Law
Selected to Super Lawyers: 2016 - 2017, 2025 - 2026 Lindon Law Corporation
4010 Prado Del TrigoCalabasas, CA 91302 Phone: 818-225-9155 Email: Mark Lindon Visit website
Boasting over three decades and billions of dollars of business transactions, Mark has a track record of successfully closing deals, comprising M&A, private equity, financings, securities offerings, licensing, distribution and joint ventures, among others. He regularly provides counsel and strategy to boards, companies and entrepreneurs on a wide variety of matters including transactions, operations and litigation. His vast experience and knowledge covers a range of dynamic sectors such as private equity, medtech, technology, apparel, finance, investment banking, investment management, manufacturing, steel fabrication and executive compensation, and is value-added to any client transaction.
An entrepreneur at heart, Mark grasps the business and legal imperatives of clients. He co-founded AndMark Management private equity and serves as its General Counsel. His previous roles include Chairman and General Counsel for a leading medical device company founded and majority-owned by renown billionaire Alfred E. Mann; serving as Mr. Mann’s personal legal advisor for years; and serving on the board of a notable Israeli medical device company. Mark began his career at a large New York based law firm where he spent 8 years in the Corporate department, and then co-founded his own firm.
Mark regularly represents companies in M&A sale transactions to large public and private companies, international conglomerates and private equity funds. He is accustomed to contending with large law firms as opposing counsel and is unfazed by their tactics.
Mark’s ethos is encapsulated in his firm’s motto "WE GET IT DONE," reflecting his commitment to vigorously represent his clients and close their transactions.
Mark has achieved the Martindale-Hubbell AV Preeminent Peer Review Rating, the highest possible rating for professional achievement and ethical standards. (https://www.martindale.com/attorney/mark-lindon-4881748/).
Mark has been selected to the Southern California Super Lawyers list for 4 years (2016, 2017, 2025 & 2026). This distinction is awarded to no more than 5% of attorneys in the state. (https://profiles.superlawyers.com/california/calabasas/lawyer/mark-lindon/e54b21f2-66db-4327-9d59-3d3b6a0a4981.html).
Practice areas
Business/Corporate, Mergers & Acquisitions, Closely Held Business, Securities & Corporate FinanceFirst Admitted: 1985, California
Professional Webpage: http://www.lindonlaw.net/biography.html
Bar / Professional Activity
- Member of the Business Law section of the California Lawyers Association.
Transactions
- Represented LiveMore Superfoods in sale to Valle Frio SpA of Chile (a subsidiary of Empresas Copec, S.A.), and structured founder's 20% equity rollover with put/call options. , 2024
- Represented Steve Hanson Landscaping in sale to Kian Capital / Diamond Landscaping., 2023
- Represented Seybert’s Billiards Corporation in four strategic acquisitions from 2022 - 2024., 2024
- Represented Doheny Eye Institute in creation of the RIMR AMD Consortium. , 2023
- Represented Edge Capital in acquisition of Cruise & Tour , 2022
- Represented executive officer in restructuring of private equity portfolio company, 2022
- Represented AndMark Management and AndMark Investment Fund VI private equity fund in $150 million private offering., 2022
- Represented closely-held defendant corporation in shareholder litigation, created strategy for and successfully executed taking control of Board and worked with litigation counsel to settle case, 2022
- Represented Moa Capital (private equity) in acquisition of Seybert’s Billiards Corporation., 2021
- Represented G64 Ventures in sale of ArborBridge (online test prep & tutoring) to Private Prep, 2021
- Represented Trillen Medical in license of medtech IP from The Regents of the University of California through the UCLA Technology Development Group , 2021
- Represented Moa Capital in acquisition of PriMetrica (leading telecom market research and analysis company), 2021
- Represented G64 Ventures in acquisition of in acquisition of PanicTap safety device, 2020
- Represented executive officer joining private equity portfolio company, restructured deal for tax efficiency, and contingent equity control agreement, 2020
- Represented PERC equity owners in sale of minority equity interest to Essilor Labs (a subsidiary of EssilorLuxottica) , 2020
- Represented PerQflo (Al Mann microinfusion pump medtech company) in sale to Medtronic, 2019
- Represented Chaser Brand (apparel company) in multiple acquisitions , 2019
- Represented PERC equity owners in structuring multi-year put/call options on owners' minority equity interests with Essilor Labs (a subsidiary of EssilorLuxottica) , 2016
- Represented PERC eyecare GPO in sale of majority equity to Essilor Labs (a subsidiary of EssilorLuxottica), and negotiated operating agreement safeguards and restrictions protecting minority interests, 2016
- Represented Doheny Eye Institute in connection with a multi-year Technology and Intellectual Property Rights License Agreement with a Chinese ophthalmic center licensee., 2015
- Represented PERC (Professional Eyecare Resource Co-operative) eyecare GPO entities in corporate restructuring., 2015
- Represented Al Mann in debt restructuring of Eclipse Aerospace, 2014
- Represented Doheny Eye Institue in its 99-year affiliation with UCLA Health and the Jules Stein Eye Institute, 2013
- Represented Quallion (Al Mann medtech aerospace and defense battery and power solutions co.) in sale to EnerSys Power Solutions, 2013
- Represented Stellar Microelectronics (Al Mann microelectronics manufacturer) in sale to Flex, 2012
- Represented Bioness in licensing $100 million microstimulator device and related manufacturing rights agreement, 2008
- Represented Bioness (Al Mann neuromodulation medtech company) in its 15-month acquisition of NESS (prominent Israeli medical device manufacturer), 2007
Educational Background
- Mark received his A.B. degree from Georgetown University where he graduated magna cum laude in interdisciplinary studies (government, economics and philosophy) and played rugby for seven seasons.
Other Outstanding Achievements
- CO-FOUNDER, GENERAL COUNSEL and STRATEGIC ADVISOR of ANDMARK MANAGEMENT private equity, from 2015 to present. The six ANDMARK FUNDS (managed by AndMark Management) have engaged in $1.5 - $2 billion of real estate investment transactions (purchases, financings and sales). , 2025
- CHAIRMAN OF THE BOARD of BIONESS INC. from 2017 to 2021. BIONESS is a prominent medical device company in Valencia, CA. Bioness was founded by and majority-owned by Alfred E. Mann, world-renowned entrepreneur and medical device multi-billionaire. It was sold in 2021., 2021
- BOARD OF DIRECTORS of BIONESS INC. Board member from 2016 until 2021. Bioness is a prominent medical device company in Valencia, CA. Bioness was founded by and majority-owned by Alfred E. Mann, world-renowned entrepreneur and medical device multi-billionaire. It was sold in 2021., 2021
- BOARD OF DIRECTORS of BIONESS NEUROMODULATION, LTD., from 2017-2021. BIONESS NEUROMODULATION is the Israeli subsidiary of BIONESS INC., a prominent medical device company in Valencia, CA founded by and majority-owned by Alfred E. Mann, world-renowned entrepreneur and medical device multi-billionaire. , 2021
Industry Groups
- Apparel
- Finance
- Healthcare Affiliations
- Medical Devices
- Mobile Applications
- Personal Care and Manufacturing
- Private Equity
- Technology
Office location for Mark Lindon
4010 Prado Del Trigo
Calabasas, CA 91302
Selections
- Super Lawyers: 2016 - 2017, 2025 - 2026